Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• p53 is a crucial tumor suppressor gene mutated in over 50% of human cancers.
• Mutations in p53 can lead to loss of tumor suppression and gain-of-function oncogenic activities.
• Cancer cells with non-functional p53 rely on the G2/M checkpoint, making them susceptible to specific inhibitors.

Purpose of the Study:

• To review recent advancements in targeting p53-mutated cancers.
• To explore the therapeutic potential of Wee1 inhibitors and statins.
• To discuss strategies targeting downstream pathways of mutated p53 (Mutp53).

Main Methods:

• Review of current literature on Wee1 inhibitors, statins, and mevalonate pathway inhibitors.
• Analysis of mechanisms by which these drugs affect cell cycle checkpoints and protein degradation.
• Examination of therapeutic strategies in the context of p53 mutations.

Main Results:

• Wee1 inhibitors target the G2/M checkpoint, inducing mitotic catastrophe in p53-deficient cancer cells.
• Statins, via the mevalonate pathway, can induce degradation of gain-of-function mutated p53 (GOF Mutp53).
• Targeting downstream pathways of Mutp53 presents a viable therapeutic approach.

Conclusions:

• Wee1 inhibitors and statins represent promising therapeutic avenues for p53-mutated cancers.
• Understanding Mutp53 gain-of-function activities informs targeted treatment strategies.
• Further research into these inhibitors could lead to novel cancer treatments.